Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Rituximab 165Cyclophosphamide 163fludarabine phosphate 95Peripheral Blood Stem Cell Transplantation 88Filgrastim 72Etoposide 65Mycophenolic Acid 63Whole-Body Irradiation 62Cytarabine 59Cyclosporine 53Melphalan 52Tacrolimus 47Busulfan 43Radiotherapy 42Lenalidomide 42Bortezomib 40ibrutinib 39fludarabine 39Methotrexate 38Antilymphocyte Serum 38Carmustine 37Bendamustine Hydrochloride 35Vincristine 33Doxorubicin 32Dexamethasone 32Granulocyte Colony-Stimulating Factor 29Prednisone 26Cord Blood Stem Cell Transplantation 25venetoclax 22obinutuzumab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Mantle-Cell × Lisaftoclax × Clear all
NCT07272499 2025-12-09

Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease

Ruijin Hospital

Phase 2 Recruiting
25 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡